On-X Life Technologies, Inc. Release: EACTS Report - Prospective Randomized On-X Heart Valve Clinical Trial (PROACT) Provides Evidence of Reduced Complications

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

VIENNA--(BUSINESS WIRE)--On-X® Life Technologies, Inc. (On-X LTI) announced today that it is highlighting the recent interim results the PROACT (Prospective Randomized On-X Anticoagulation Clinical Trial) at the European Association of Cardio-Thoracic Surgeons Meeting being held October 5-9, 2013, in Vienna, Austria.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC